Following a full submission
AWMSG advice |
|
| Status: Not recommended | |
Human alpha1-proteinase inhibitor (Respreeza®) is not recommended for use within NHS Wales for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). The case for clinical effectiveness and cost-effectiveness has not been proven. |
|
Medicine details |
|
| Medicine name | human alpha1-proteinase inhibitor (Respreeza®) |
| Formulation | 1000 mg powder and solvent for solution for infusion |
| Reference number | 47 |
| Indication | Maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency. |
| Company | CSL Behring UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | Full |
| Status | Not recommended |
| Advice number | 0217 |
| NMG meeting date | 05/10/2016 |
| AWMSG meeting date | 15/02/2017 |
| Date of issue | 21/03/2017 |